Introduction

A domestic leading cell therapy company is currently preparing to apply for IND for its TCR-T pipeline, one of its main pipelines. Among them, in the cell processing stage, they want to acheive the domestic replacement of automated equipment and focus on automating the processing of blood samples to concentrate cells, remove platelets, and separate PBMCs.

Challenges with the current solution include:

The current protocol only accommodates samples of a specific volume, but the initial volume of patient samples is often uncertain, leading to the potential wastage of precious excess samples.

There is a need to efficiently remove platelets from the sample, as any residual platelets could impact T cell proliferation.
The existing protocol lacks support for direct sampling after cell processing, making quality control operations cumbersome.

General protocols

Based on customer requirements, the EurekaBio APDC (Automated Product Delivery Center) Team delivers a comprehensive CAS (Customized Application Service), providing the customer with a tailored solution that includes two customized software programs:

1. They add a "Blood Sample Pretreatment" process software that can concentrate blood samples of varying volumes to a specified volume. This software also includes a step for washing the blood sample during operation to remove platelets.
2. They optimize the "PBMC Isolation" process by incorporating a sampling step after PBMC separation is completed.